Medicine and Dentistry
Neoplasm
100%
Hepatocellular Carcinoma
98%
Nivolumab
83%
Tumor Microenvironment
73%
Pancreas Adenocarcinoma
68%
Pancreas Cancer
65%
Ipilimumab
57%
Surgery
48%
Immunotherapy
45%
Cabozantinib
40%
Macrophage
40%
Immune Checkpoint Inhibitor
38%
Programmed Death-Ligand 1
38%
Pembrolizumab
34%
Malignant Neoplasm
33%
Head and Neck Squamous Cell Carcinoma
32%
Prurigo nodularis
32%
Immunohistochemistry
31%
CD8 Antigen
27%
Cytotoxic T-Cell
26%
Squamous Cell
24%
Neck
24%
Cancer Cell
24%
Lymphocyte
24%
Metastatic Carcinoma
24%
CTLA-4
22%
RNA Sequence
21%
Disease
21%
Pancreatic Ductal Adenocarcinoma
21%
Biological Marker
21%
Recurrent Disease
20%
Cancer Immunotherapy
20%
Solid Malignant Neoplasm
20%
Neoadjuvant Therapy
20%
Arm
19%
Immune-Related Adverse Events
19%
Mass Cytometry
18%
Transcriptomics
18%
T Cell
17%
Stomach Carcinoma
16%
Cholangiocarcinoma
16%
Tumor Vaccine
16%
Quality of Life
16%
Cellular Imaging
16%
Cancer Immunology
16%
Liver Function
16%
Pancreas Tumor
16%
Stomach Cancer
16%
Cancer Therapy
16%
Epstein-Barr Virus
16%
Keyphrases
Hepatocellular Carcinoma
71%
Tumor
66%
Nivolumab
64%
Tumor Microenvironment
64%
Ipilimumab
62%
Advanced Hepatocellular Carcinoma
49%
Anti-PD-1
45%
Tumor Immunity
41%
Pembrolizumab
34%
Pancreatic Tumor
32%
Tumor Model
32%
Renal Cell Carcinoma
32%
Neoadjuvant
32%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
32%
Spatial Landscape
32%
Prurigo Nodularis
32%
Pancreatic Cancer
32%
Pancreatic Ductal Adenocarcinoma
27%
Cancer Immunotherapy
26%
Head-and-neck
24%
B Cells
24%
Immune System
24%
Drug Resistance
24%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
22%
Anti-PD-1 Therapy
22%
Cancer Cells
22%
Chemotherapy
21%
Programmed Death-ligand 1 (PD-L1)
21%
Basic Fibroblast Growth Factor (bFGF)
20%
Solid Tumors
20%
Overall Response Rate
19%
Progression-free Survival
19%
CTLA-4 Blockade
19%
Immune Microenvironment
19%
Locally Advanced
19%
Immune Checkpoint Inhibitor Therapy
19%
Poor Prognosis
18%
Immune Cells
18%
Squamous Cell Cancer
18%
Natural Killer Cells
17%
Micronutrients
17%
Gastric Carcinoma
16%
Single-center Analysis
16%
EBV-positive
16%
Fibroblasts
16%
Polymeric Scaffolds
16%
Hepatic Function
16%
Accession number
16%
Computational Analysis
16%
15-hydroxyprostaglandin Dehydrogenase (15-PGDH)
16%
Immunology and Microbiology
T Cell
85%
Mouse
71%
Mass Cytometry
65%
Macrophage
44%
Immunotherapy
44%
Lymph Node
41%
Immunocompetent Cell
38%
Cell Death
36%
Cabozantinib
32%
B Cell
31%
Cytotoxic T-Cell
28%
RNA Sequence
28%
Mouse Model
27%
Natural Killer Cell
24%
Immune System
24%
Cancer Cell
24%
Lymphocyte
24%
Cancer Immunotherapy
22%
Syngenic
21%
Cell Interaction
20%
Cancer Immunology
20%
Immunosuppressive Drug
20%
Vaccine Efficacy
19%
Programmed Death-Ligand 1
18%
Fibroblast
16%
Multi-Omics
16%
Tumor Immunity
16%
CTLA-4
16%
CD8
16%
Interleukin 15
16%
Programmed Death 1 Ligand 1
16%
Phenotype
16%
Nivolumab
16%
Molecular Interaction
16%
Tumor Cell
16%
B Cell Activating Factor
16%
Liver Function
16%
CD14
16%
Neoantigen
16%
Chimeric Antigen Receptor Natural Killer Cell
16%
Cancer Staging
16%
Programmed Death 1 Receptor
16%
Stem Cell
16%
Immunology
16%
Dynamics
12%
CD98
12%
Transfer of Learning
12%
CD29
12%
Immune Response
11%
Dermatitis
10%
